Financial Results Approval
The Board approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2026, along with year-to-date figures for the period from 1st April, 2026, to 30th June, 2026, together with the Limited Review Report (Annexure-A).
Standalone Financial Performance (Rs. in Lacs)
- Total Income: ₹390.54 (Q1 FY27) vs ₹152.00 (Q4 FY26) vs ₹1122.17 (Q1 FY26)
- Total Expenses: ₹313.74 (Q1 FY27) vs ₹205.07 (Q4 FY26) vs ₹1089.28 (Q1 FY26)
- Profit before tax: ₹76.80 (Q1 FY27) vs -₹53.07 (Q4 FY26) vs ₹32.89 (Q1 FY26)
- Tax Expense: ₹0.00 (Q1 FY27) vs ₹14.33 (Q4 FY26) vs ₹0.00 (Q1 FY26)
- Net Profit: ₹76.80 (Q1 FY27) vs -₹67.40 (Q4 FY26) vs ₹32.89 (Q1 FY26)
- Earnings Per Share (Basic): ₹0.06 (Q1 FY27) vs -₹0.05 (Q4 FY26) vs ₹0.03 (Q1 FY26)
- Paid-up equity share capital: ₹1288.25 lacs (unchanged across all periods)
Consolidated Financial Performance (Rs. in Lacs)
- Total Income: ₹8076.27 (Q1 FY27) vs ₹3928.07 (Q4 FY26) vs ₹7656.62 (Q1 FY26)
- Total Expenses: ₹7978.45 (Q1 FY27) vs ₹3980.64 (Q4 FY26) vs ₹7602.69 (Q1 FY26)
- Profit before tax: ₹97.82 (Q1 FY27) vs -₹52.57 (Q4 FY26) vs ₹53.94 (Q1 FY26)
- Tax Expense: ₹0.00 (Q1 FY27) vs ₹27.80 (Q4 FY26) vs ₹0.00 (Q1 FY26)
- Net Profit: ₹97.82 (Q1 FY27) vs -₹80.37 (Q4 FY26) vs ₹53.94 (Q1 FY26)
Other Board Approvals and Notings
1. Noted disclosure of interest received from Directors pursuant to Section 184 of the Companies Act, 2013
2. Noted intimation of disqualification under Section 164 of the Companies Act, 2013
3. Noted declarations from Independent Directors confirming independence criteria under Section 149(7) of Companies Act, 2013 and Regulation 25(8) of SEBI LODR
4. Noted issuance of Duplicate Share Certificate to Mr. Rajesh Bhanji Lakum under Regulation 39(3) of SEBI LODR
5. Noted execution of Business Collaboration agreements with Qness Pharmaceuticals (a proprietorship concern) for manufacture, supply, branding and marketing of pharmaceutical and allied products
6. Noted Corporate Governance Report for quarter ended 30th June, 2026 pursuant to Regulation 27(2) of SEBI LODR
7. Noted e-form DPT-3 (Return of Deposits) for financial year ended 31st March, 2026 to be filed with Registrar of Companies
8. Approved authorization to open Trading Account and Demat Account with Motilal Oswal Financial Services Limited (MOFSL)
9. Approved authorization for Mr. H.A. Parikh (Managing Director), Mr. Jainil Bhatt (Director), and Mr. Devang Shah (Company Secretary & Compliance Officer) to severally sign, execute and file statutory documents with various authorities until next AGM
Auditor's Review
The limited review was conducted by GMCA & Co., Chartered Accountants (FRN: 109850W) who stated that nothing came to their attention causing them to believe the financial statements contain material misstatement. The review was conducted in accordance with SRE 2410 issued by ICAI.
Business Segment Disclosure
The Company operates in a single reportable business segment with diversified activities comprising construction and infrastructure development, pharmaceuticals and healthcare, and trading/manufacturing of agro, renewable energy, technology, and infrastructure-related products and services.
Subsidiaries and Joint Ventures
The consolidated results include CKIM PHARMA LLP (Joint Venture) and Trinity Ganesh Private Limited (Subsidiary).